Short answer
Vertex Pharmaceuticals (VRTX) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $3.3B (up 12.5% year over year) with net income of $1.1B.
Q2 2026 key financials · XBRL
- Revenue
- $3.3B
- +12.5% YoY · +11.6% QoQ
- Net income
- $1.1B
- +6.5% YoY · +6.6% QoQ
- Operating margin
- 37.4%
- EPS (diluted)
- $4.31
- +8.0% YoY · +7.2% QoQ
Source: XBRL data from the Vertex Pharmaceuticals (VRTX) Q2 2026 10-Q on SEC EDGAR. USD.
Vertex Pharmaceuticals Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New financing risk triggered by Crinetics acquisition: $4.5B term loan, with $1.0B maturing within 364 days
- Most material financial update: leverage covenant of 3.50-to-1.00, temporarily expandable to 4.00-to-1.00 after material acquisitions
- Regulatory and compliance risk: 2026 Revolver includes subsidiary-debt, lien, and fundamental-change restrictions
- Liquidity risk: $500M revolving facility matures July 30, 2031, with up to $100M available in alternative currencies
- Interest-rate risk: term-loan SOFR margins range from 0.8750% to 1.625% based on leverage or credit rating
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vertex Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.